CVS Health (CVS) Stock Forecast & Price Target

Q: What analysts cover CVS Health?

CVS Health has been rated by research analysts at Argus , Barclays , BMO Capital Markets , Cantor Fitzgerald , JPMorgan Chase & Co. , Piper Sandler , Robert W. Baird , Sanford C. Bernstein , Truist Financial , UBS Group , Weiss Ratings , and Wells Fargo & Company in the past 90 days.

$88.39 +0.44 (+0.50%)

As of 01:18 PM Eastern

Compare

CVS Health - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 23 Analyst Ratings

Sell
0

Hold
1

Buy
22

Based on 23 Wall Street analysts who have issued ratings for CVS Health in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 23 analysts, 1 has given a hold rating, and 22 have given a buy rating for CVS.

Consensus Price Target

$107.24
21.33% Upside

According to the 23 analysts' twelve-month price targets for CVS Health, the average price target is $107.24. The highest price target for CVS is $123.00, while the lowest price target for CVS is $90.00. The average price target represents a forecasted upside of 21.33% from the current price of $88.39.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for CVS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for CVS Health and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CVS Analyst Ratings Over Time

Type	Current Forecast 10/8/25 to 10/8/26	1 Month Ago 9/8/25 to 9/8/26	3 Months Ago 7/10/25 to 7/10/26	1 Year Ago 10/8/24 to 10/8/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	22 Buy rating(s)	22 Buy rating(s)	21 Buy rating(s)	17 Buy rating(s)
Hold	1 Hold rating(s)	2 Hold rating(s)	4 Hold rating(s)	4 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$107.24	$106.83	$102.84	$79.20
Forecasted Upside	21.33% Upside	11.15% Upside	-1.25% Downside	2.94% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

CVS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

CVS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

CVS Health Stock vs. The Competition

Type	CVS Health	Healthcare Companies	Broader Market
Consensus Rating Score	2.96	2.32	2.52
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	22.16% Upside	856.72% Upside	20.58% Upside
News Sentiment Rating	Positive News See Recent CVS News	Neutral News	Neutral News

Recent Analyst Forecasts and Stock Ratings

Show

Rating

Upside/Downside

Action

Report Date

0 Results

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
10/1/2026	Cantor Fitzgerald 5 of 5 stars	Sarah James 3 of 5 stars	Reiterated Rating	Overweight
9/22/2026	UBS Group 4 of 5 stars	Kevin Caliendo 3 of 5 stars	Reiterated Rating	Buy
9/9/2026	BMO Capital Markets 3 of 5 stars		Set Target		$112.00	+18.06%
9/9/2026	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jessica Tassan Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$112.00	+18.06%
9/9/2026	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lance Wilkes Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform	$112.00	+19.98%
8/19/2026	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Steve Silver Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$104.00 ➝ $114.00	+19.92%
8/12/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lisa Gill Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$111.00 ➝ $118.00	+26.09%
8/6/2026	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Ha Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$107.00	+10.60%
8/6/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Andrew Mok Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$106.00 ➝ $108.00	+8.83%
8/5/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold (C+) ➝ Buy (B-)
Get the Latest News and Ratings for CVS and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for CVS Health and its competitors with MarketBeat's FREE daily newsletter.
7/14/2026	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David MacDonald Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$108.00 ➝ $118.00	+11.26%
7/13/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Stephen Baxter Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$103.00 ➝ $123.00	+18.10%
7/9/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ben Hendrix Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$107.00 ➝ $113.00	+8.33%
7/6/2026	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Hold	$103.00	+0.72%
6/22/2026	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Allen Lutz Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$100.00 ➝ $110.00	+7.54%
6/8/2026	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ann Hynes Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$110.00 ➝ $115.00	+20.18%
6/4/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Erin Wright Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$106.00 ➝ $111.00	+21.17%
5/11/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Charles Rhyee Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$105.00 ➝ $110.00	+20.18%
5/7/2026	DA Davidson Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Buy	$80.00 ➝ $100.00	+14.05%
5/7/2026	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Buy	$88.00 ➝ $92.00	+4.93%
3/5/2026	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Cherny Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform	$98.00	+23.58%
3/2/2026	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Outperform	$100.00 ➝ $97.00	+20.86%
2/12/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Scott Fidel Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$95.00 ➝ $97.00	+23.39%
10/31/2025	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target		$75.00 ➝ $90.00	+15.20%
10/30/2025	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target		$92.00 ➝ $98.00	+25.44%
10/30/2025	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Elizabeth Anderson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$85.00 ➝ $95.00	+22.55%
9/8/2025	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Strong-Buy ➝ Hold
7/16/2025	Bernstein Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Market Perform	$78.00 ➝ $72.00	+12.86%
1/30/2025	Edward Jones Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold ➝ Buy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 01:18 PM ET.

Should I Buy CVS Health Stock? CVS Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, October 5, 2026. Please send any questions or comments about these CVS Health pros and cons to contact@marketbeat.com.

CVS Health
Bull Case

Here are some ways that investors could benefit from investing in CVS Health Co.:

CVS Health Co. recently demonstrated strong fundamental performance by beating analyst expectations in its most recent quarterly report, delivering earnings per share of $2.58 against a consensus estimate of $1.87 and generating revenue of $106.10 billion, which exceeded the projected $100.03 billion. This significant positive surprise, combined with a year-over-year revenue growth of 7.3%, suggests the company is successfully executing its operational strategy and generating higher-than-anticipated profits for shareholders.
The stock currently trades at $86.94, which is significantly below the consensus price target of $107.24 held by twenty-two research analysts who have rated the stock with a Buy rating. This substantial gap between the current market price and the average analyst target implies that the market may be undervaluing the company's potential, offering investors a potential opportunity for capital appreciation as the stock price converges with these higher expectations.
CVS Health Co. offers a compelling income stream for investors through its dividend, which currently yields 3.08%. The company recently declared a quarterly dividend of $0.6650 per share, representing an annualized payout of $2.66. This consistent cash distribution provides a tangible return on investment and can serve as a stabilizing factor for the total return profile, particularly for income-focused portfolios.
Institutional investors are showing renewed confidence in the company, with Argent Capital Management LLC increasing its position in CVS Health Co. by 50.4% during the third quarter. This significant accumulation of shares by a major institutional player, alongside similar increases by other firms like Elevation Wealth Partners LLC, indicates that professional money managers are identifying value in the stock and are actively adding to their holdings.
The company has secured long-term strategic partnerships that support its business stability, such as the binding Letter of Intent with Cardinal Health to extend their pharmaceutical distribution agreement through June 30, 2032. This long-term commitment ensures a reliable supply chain for CVS Health Co.'s pharmacy operations and reinforces its position as a key player in the healthcare distribution network, reducing operational uncertainty for the foreseeable future.

CVS Health
Bear Case

Investors should be bearish about investing in CVS Health Co. for these reasons:

CVS Health Co. is currently trading at $86.94, which is well below its 50-day moving average of $94.68 and its 200-day moving average of $92.01. When a stock price is below these key technical indicators, it often signals a downward trend or bearish momentum, suggesting that recent selling pressure has outweighed buying interest and that the stock may continue to face headwinds in the near term.
Despite the recent earnings beat, the stock experienced a significant gap down of 10.7% on August 5, 2026, falling from a previous close of $104.42 to $98.14. This sharp decline following the earnings release indicates that the market may have already priced in the positive results or that investors are concerned about the sustainability of the company's performance, leading to a rapid revaluation of the stock's worth.
Short interest in CVS Health Co. has been relatively high, with 16,123,980 shares shorted as of the most recent record date. A high level of short interest means that a significant number of investors are betting against the stock, which can create downward pressure on the price and increase volatility, particularly if the company fails to meet future expectations or if broader market conditions deteriorate.
The company's financial health shows some strain, with a current ratio of 0.87 and a quick ratio of 0.66, both of which are below 1.0. These ratios indicate that CVS Health Co. has fewer current assets than current liabilities, meaning it may face challenges in meeting its short-term obligations without relying on the sale of inventory or other non-liquid assets, which could be a concern for risk-averse investors.
CVS Health Co. has a high dividend payout ratio of 70.37%, meaning the company is distributing a large portion of its earnings as dividends to shareholders. While this is attractive for income investors, it leaves less capital available for reinvestment in the business, research and development, or debt reduction, which could limit the company's long-term growth potential and flexibility in responding to market changes.

CVS Forecast - Frequently Asked Questions

According to the research reports of 23 Wall Street equities research analysts, the average twelve-month stock price forecast for CVS Health is $107.24, with a high forecast of $123.00 and a low forecast of $90.00.

23 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CVS Health in the last twelve months. There is currently 1 hold rating and 22 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CVS shares.

According to analysts, CVS Health's stock has a predicted upside of 21.33% based on their 12-month stock forecasts.

Over the previous 90 days, CVS Health's stock had 2 upgrades by analysts.

CVS Health has been rated by research analysts at Argus, Barclays, BMO Capital Markets, Cantor Fitzgerald, JPMorgan Chase & Co., Piper Sandler, Robert W. Baird, Sanford C. Bernstein, Truist Financial, UBS Group, Weiss Ratings, and Wells Fargo & Company in the past 90 days.

Analysts like CVS Health more than other "healthcare" companies. The consensus rating for CVS Health is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how CVS compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With CVS Health Recommendations

MarketBeat monitors more than a dozen sources for CVS Health analyst ratings, with the most recent rating issued on 10/1/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CVS Health (CVS) Stock Forecast & Price Target